XFOR Insider Trading Activity and SEC Form 4 Filings
XFOR insider trading summary
Over the past 12 months, insiders at X4 Pharmaceuticals, Inc (XFOR) reported 5 sales worth $463K by 3 insiders and 1 open-market purchase worth $12K by 1 insider on SEC Form 4. Net insider selling was $451K.
Latest XFOR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 16, 2026 | Adam R Craig | Executive Chairman | Buy | $12K (4,600 @ $2.58) |
| Oct 1, 2026 | David Kirske | Chief Financial Officer | Sell | $34K (11,767 @ $2.86) |
| Aug 12, 2026 | Adam R Craig | Executive Chairman | Sell | $211K (47,436 @ $4.44) |
| Aug 12, 2026 | John Volpone | President | Sell | $109K (24,576 @ $4.44) |
| Jun 30, 2026 | David Kirske | Chief Financial Officer | Sell | $36K (8,543 @ $4.26) |
| May 12, 2026 | David Kirske | Chief Financial Officer | Sell | $73K (16,961 @ $4.29) |
| Oct 23, 2025 | Adam R Craig | Executive Chairman | Buy | $250K (86,206 @ $2.90) |
| May 16, 2025 | Mark Baldry | Chief Commercial Officer | Buy | $3K (1,032 @ $2.48) |
| Jan 24, 2025 | Paula Ragan | President and CEO | Sell | $35K (76,473 @ $0.45) |
| Jan 24, 2025 | Mary DiBiase | Chief Operating Officer | Sell | $10K (22,258 @ $0.45) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.